313 related articles for article (PubMed ID: 6140716)
1. [Metamorphosis of chronic myeloproliferative diseases].
Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
[No Abstract] [Full Text] [Related]
2. [Clinical conference: Histaaminemia in myeloproliferative syndromes].
Cadiou M; Ruff F; Meunier F; Attalah N; Bernadou A; Zittoun R; Parrot JL; Bousser J
Nouv Rev Fr Hematol; 1975; 15(2):261-9. PubMed ID: 126436
[No Abstract] [Full Text] [Related]
3. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
[No Abstract] [Full Text] [Related]
4. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
5. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
6. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
7. Natural history of chronic granulocytic leukaemia.
Moloney WC
Clin Haematol; 1977 Feb; 6(1):41-53. PubMed ID: 334416
[No Abstract] [Full Text] [Related]
8. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
9. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
10. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
11. Erythromelalgia--a thrombotic complication in chronic myeloproliferative disorders.
Tarach JS; Nowicka-Tarach BM; Matuszek B; Nowakowski A
Med Sci Monit; 2000; 6(1):204-8. PubMed ID: 11208311
[TBL] [Abstract][Full Text] [Related]
12. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
13. Myeloproliferative neoplasms cause glomerulopathy.
Said SM; Leung N; Sethi S; Cornell LD; Fidler ME; Grande JP; Herrmann S; Tefferi A; D'Agati VD; Nasr SH
Kidney Int; 2011 Oct; 80(7):753-9. PubMed ID: 21654720
[TBL] [Abstract][Full Text] [Related]
14. [Comprehensive care of patients with thrombocythemia].
Hrubisková K; Steruská M; Horváth A
Vnitr Lek; 1987 Oct; 33(10):872-82. PubMed ID: 3479860
[No Abstract] [Full Text] [Related]
15. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
16. Development of polycythemia vera in a patient with myeloid metaplasia and myelofibrosis. Report of a case with a comment on its significance in relation to prevailing views on myeloid metaplasia.
Hershko C; Polliack A
Isr J Med Sci; 1971 Feb; 7(2):315-20. PubMed ID: 5560987
[No Abstract] [Full Text] [Related]
17. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
18. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases.
Guilpain P; Montani D; Damaj G; Achouh L; Lefrère F; Le Pavec J; Marfaing-Koka A; Dartevelle P; Simonneau G; Humbert M; Hermine O
Respiration; 2008; 76(3):295-302. PubMed ID: 18160817
[TBL] [Abstract][Full Text] [Related]
20. [Unusual case of chronic myeloproliferative syndrome].
Tosato F; Fossaluzza V
Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]